Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 94,028 shares changing hands.
Mateon Therapeutics Stock Up 2.0 %
The firm’s 50-day moving average is $0.03 and its two-hundred day moving average is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- What does consumer price index measure?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- What is the MACD Indicator and How to Use it in Your Trading
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
